Seize the Day: How biotech companies can leverage pharma’s patent cliff

The imminent expiration of patents for major pharmaceutical drugs, known as the "patent cliff," not only opens the market for lower-priced generics but also presents a prime opportunity for biotech companies to secure valuable partnerships with pharma as they seek to revitalise their portfolios  .....